|
1
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.
|
|
3
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar
|
|
4
|
Galle PR, Dufour JF, Peck-Radosavljevic M,
Trojan J and Vogel A: Systemic therapy of advanced hepatocellular
carcinoma. Future Oncol. 17:1237–1251. 2021. View Article : Google Scholar
|
|
5
|
Gordan JD, Kennedy EB, Abou-Alfa GK, Beal
E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, et al:
Systemic therapy for advanced hepatocellular carcinoma: ASCO
guideline update. J Clin Oncol. 42:1830–1850. 2024. View Article : Google Scholar
|
|
6
|
Tian Z, Niu X and Yao W: Efficacy and
response biomarkers of apatinib in the treatment of malignancies in
China: A review. Front Oncol. 11:7490832021. View Article : Google Scholar
|
|
7
|
Li D, Xu L, Ji J, Bao D, Hu J, Qian Y,
Zhou Y, Chen Z, Li D, Li X, et al: Sintilimab combined with
apatinib plus capecitabine in the treatment of unresectable
hepatocellular carcinoma: A prospective, open-label, single-arm,
phase II clinical study. Front Immunol. 13:9440622022. View Article : Google Scholar
|
|
8
|
Xia WL, Zhao XH, Guo Y, Cao GS, Wu G, Fan
WJ, Yao QJ, Xu SJ, Guo CY, Hu HT and Li HL: Transarterial
chemoembolization combined with apatinib with or without PD-1
inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter
retrospective study. Front Oncol. 12:9613942022. View Article : Google Scholar
|
|
9
|
Song H, Liu X, Jiang L, Li F, Zhang R and
Wang P: Current status and prospects of camrelizumab, A humanized
antibody against programmed cell death receptor 1. Recent Pat
Anticancer Drug Discov. 16:312–332. 2021. View Article : Google Scholar
|
|
10
|
Qin S, Ren Z, Meng Z, Chen Z, Chai X,
Xiong J, Bai Y, Yang L, Zhu H, Fang W, et al: Camrelizumab in
patients with previously treated advanced hepatocellular carcinoma:
A multicentre, open-label, parallel-group, randomised, phase 2
trial. Lancet Oncol. 21:571–580. 2020. View Article : Google Scholar
|
|
11
|
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J,
Shao G, Zhang Y, Xu L, Yin T, et al: Camrelizumab in combination
with apatinib in patients with advanced hepatocellular carcinoma
(RESCUE): A nonrandomized, open-label, phase II trial. Clin Cancer
Res. 27:1003–1011. 2021. View Article : Google Scholar
|
|
12
|
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X,
Chen Z, Jia W, Jin Y, Guo Y, et al: Camrelizumab plus rivoceranib
versus sorafenib as first-line therapy for unresectable
hepatocellular carcinoma (CARES-310): A randomised, open-label,
international phase 3 study. Lancet. 402:1133–1146. 2023.
View Article : Google Scholar
|
|
13
|
Ayuso C, Rimola J, Vilana R, Burrel M,
Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C,
Barrufet M, et al: Diagnosis and staging of hepatocellular
carcinoma (HCC): Current guidelines. Eur J Radiol. 101:72–81. 2018.
View Article : Google Scholar
|
|
14
|
Schwartz LH, Seymour L, Litière S, Ford R,
Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et
al: RECIST 1.1-standardisation and disease-specific adaptations:
Perspectives from the RECIST working group. Eur J Cancer.
62:138–145. 2016. View Article : Google Scholar
|
|
15
|
Peng W, Pan Y, Xie L, Yang Z, Ye Z, Chen
J, Wang J, Hu D, Xu L, Zhou Z, et al: The emerging therapies are
reshaping the first-line treatment for advanced hepatocellular
carcinoma: A systematic review and network meta-analysis. Therap
Adv Gastroenterol. 17:175628482412376312024. View Article : Google Scholar
|
|
16
|
Feng T, Li Q, Zhu R, Yu C, Xu L, Ying L,
Wang C, Xu W, Wang J, Zhu J, et al: Tumor microenvironment
biomarkers predicting pathological response to neoadjuvant
chemoimmunotherapy in locally advanced esophageal squamous cell
carcinoma: Post-hoc analysis of a single center, phase 2 study. J
Immunother Cancer. 12:e0089422024. View Article : Google Scholar
|
|
17
|
Liu Q, Zhang H, Xiao H, Ren A, Cai Y, Liao
R, Yu H, Wu Z and Huang Z: Discovery of novel diagnostic biomarkers
of hepatocellular carcinoma associated with immune infiltration.
Ann Med. 57:25036452025. View Article : Google Scholar
|
|
18
|
Shigeta K, Datta M, Hato T, Kitahara S,
Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, et
al: Dual programmed death receptor-1 and vascular endothelial
growth factor receptor-2 blockade promotes vascular normalization
and enhances antitumor immune responses in hepatocellular
carcinoma. Hepatology. 71:1247–1261. 2020. View Article : Google Scholar
|
|
19
|
Ciciola P, Cascetta P, Bianco C, Formisano
L and Bianco R: Combining immune checkpoint inhibitors with
anti-angiogenic agents. J Clin Med. 9:6752020. View Article : Google Scholar
|
|
20
|
Ju S, Zhou C, Yang C, Wang C, Liu J, Wang
Y, Huang S, Li T, Chen Y, Bai Y, et al: Apatinib plus camrelizumab
with/without chemoembolization for hepatocellular carcinoma: A
real-world experience of a single center. Front Oncol.
11:8358892022. View Article : Google Scholar
|
|
21
|
Cai M, Huang W, Huang J, Shi W, Guo Y,
Liang L, Zhou J, Lin L, Cao B, Chen Y, et al: Transarterial
chemoembolization combined with lenvatinib plus PD-1 inhibitor for
advanced hepatocellular carcinoma: A retrospective cohort study.
Front Immunol. 13:8483872022. View Article : Google Scholar
|
|
22
|
Li T, Guo J, Liu Y, Du Z, Guo Z, Fan Y,
Cheng L, Zhang Y, Gao X, Zhao Y, et al: Effectiveness and
tolerability of camrelizumab combined with molecular targeted
therapy for patients with unresectable or advanced HCC. Cancer
Immunol Immunother. 72:2137–2149. 2023. View Article : Google Scholar
|
|
23
|
Yuan G, Cheng X, Li Q, Zang M, Huang W,
Fan W, Wu T, Ruan J, Dai W, Yu W, et al: Safety and efficacy of
camrelizumab combined with apatinib for advanced hepatocellular
carcinoma with portal vein tumor thrombus: A multicenter
retrospective study. Onco Targets Ther. 13:12683–12693. 2020.
View Article : Google Scholar
|
|
24
|
Mei K, Qin S, Chen Z, Liu Y, Wang L and
Zou J: Camrelizumab in combination with apatinib in second-line or
above therapy for advanced primary liver cancer: Cohort A report in
a multicenter phase Ib/II trial. J Immunother Cancer.
9:e0021912021. View Article : Google Scholar
|
|
25
|
Chen D, Chen X, Xu L, Wang Y, Zhu L and
Kang M: Camrelizumab combined with apatinib in the treatment of
patients with hepatocellular carcinoma: A real-world assessment.
Neoplasma. 70:580–587. 2023. View Article : Google Scholar
|
|
26
|
He MK, Zou RH, Wei W, Shen JX, Zhao M,
Zhang YF, Lin XJ, Zhang YJ, Guo RP and Shi M: Comparison of stable
and unstable ethiodized oil emulsions for transarterial
chemoembolization of hepatocellular carcinoma: Results of a
single-center double-blind prospective randomized controlled trial.
J Vasc Interv Radiol. 29:1068–1077.e2. 2018. View Article : Google Scholar
|
|
27
|
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z,
Xu A, Chen X, Zhou C, Ren Z, et al: Apatinib as second-line or
later therapy in patients with advanced hepatocellular carcinoma
(AHELP): A multicentre, double-blind, randomised,
placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol.
6:559–568. 2021. View Article : Google Scholar
|
|
28
|
Hou Z, Zhu K, Yang X, Chen P, Zhang W, Cui
Y, Zhu X, Song T, Li Q, Li H and Zhang T: Apatinib as first-line
treatment in patients with advanced hepatocellular carcinoma: A
phase II clinical trial. Ann Transl Med. 8:10472020. View Article : Google Scholar
|
|
29
|
Jin ZC, Zhong BY, Chen JJ, Zhu HD, Sun JH,
Yin GW, Ge NJ, Luo B, Ding WB, Li WH, et al: Real-world efficacy
and safety of TACE plus camrelizumab and apatinib in patients with
HCC (CHANCE2211): A propensity score matching study. Eur Radiol.
33:8669–8681. 2023. View Article : Google Scholar
|
|
30
|
Chen ICY, Dungca LBP, Yong CC and Chen CL:
Sequential living donor liver transplantation after liver resection
optimizes outcomes for patients with high-risk hepatocellular
carcinoma. Hepatobiliary Pancreat Dis Int. 24:50–56. 2025.
View Article : Google Scholar
|
|
31
|
Zhu HK, Mou HB, Wang ZY, Zhang W, Zhu D,
Zhong SY, Zheng SS and Zhuang L: Adjuvant chemotherapy improves
post-transplant outcome in patients with hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. S1499-3872(25)00093-1. 2025.(Epub
ahead of print). View Article : Google Scholar
|
